(S)-4-(tert-butyldimethylsilyloxy)-2-(3-(hex-5-enyl)-3-methylureido)butanoic acid | 1108657-87-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4-(tert-butyldimethylsilyloxy)-2-(3-(hex-5-enyl)-3-methylureido)butanoic acid
• 英文别名: (2S)-4-[tert-butyl(dimethyl)silyl]oxy-2-[[hex-5-enyl(methyl)carbamoyl]amino]butanoic acid
• CAS: 1108657-87-9
• 化学式: C₁₈H₃₆N₂O₄Si
• 分子量: 372.58
• InChiKey: UPOSXXINAHLLBG-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.85
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-4-(tert-butyldimethylsilyloxy)-2-(3-(hex-5-enyl)-3-methylureido)butanoic acid 在 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 、 偶氮二甲酸二异丙酯 、 四丁基氟化铵 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 三苯基膦 、 N,N'-羰基二咪唑 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease

  摘要：

  We disclose here the synthesis of a series of macrocyclic HCV protease inhibitors, where the homoserine linked together the quinoline P2' motif and the macrocyclic moiety. These compounds exhibit potent inhibitory activity against HCV NS3/4A protease and replicon cell based assay. Their enzymatic and antiviral activities are modulated by substitutions on the quinoline P2' at position 8 by methyl and halogens and by small heterocycles at position 2. The in vitro structure activity relationship (SAR) studies and in vivo pharmacokinetic (PK) evaluations of selected compounds are described herein. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.07.020
• 作为产物：
  描述：

  N-甲基-5-己烯-1-胺 4-甲基苯磺酸盐 在 三乙胺 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 生成 (S)-4-(tert-butyldimethylsilyloxy)-2-(3-(hex-5-enyl)-3-methylureido)butanoic acid
  参考文献：
  名称：

  Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease

  摘要：

  We disclose here the synthesis of a series of macrocyclic HCV protease inhibitors, where the homoserine linked together the quinoline P2' motif and the macrocyclic moiety. These compounds exhibit potent inhibitory activity against HCV NS3/4A protease and replicon cell based assay. Their enzymatic and antiviral activities are modulated by substitutions on the quinoline P2' at position 8 by methyl and halogens and by small heterocycles at position 2. The in vitro structure activity relationship (SAR) studies and in vivo pharmacokinetic (PK) evaluations of selected compounds are described herein. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.07.020

文献信息

• [EN] MACROCYCLIC SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SÉRINE PROTÉASE
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2009014730A1

  公开（公告）日：2009-01-29

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，Formula I的药物组合物，以及其制备方法。还提供了它们用于治疗宿主HCV感染的方法。
• MACROCYCLIC SERINE PROTEASE INHIBITORS I
  申请人：Parsy Christophe Claude

  公开号：US20090047244A1

  公开（公告）日：2009-02-19

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，公式I所示的化合物，包含这种化合物的制药组合物以及其制备过程。同时，还提供了它们用于治疗宿主中HCV感染的方法。